Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Rheum Dis. 2019 Apr;26(2):118-123. English. Original Article. https://doi.org/10.4078/jrd.2019.26.2.118
Ahn E , Lee S , Lee HN , Lee SG , So MW .
Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea. thalsdnrso@naver.com
Division of Rheumatology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
Abstract

Objective

To compare efficacy and safety of febuxostat in gouty patients with chronic kidney disease (CKD) stage 3 and stage 4/5.

Methods

Age and sex matched patients with CKD stage 3 and stage 4/5 who were diagnosed with gout were included. The dose of febuxostat was increased according to serum uric acid (sUA) level. Adherence, the number of gout attack, the change of sUA, the change of estimated glomerular filtration rate (eGFR) and adverse events (AEs) were evaluated for 12 months.

Results

There were no significant differences in the baseline variables between CKD stage 3 and CKD stage 4/5. Disease duration was longer and baseline sUA was higher in the CKD stage 4/5. There were no significant differences in the mean sUA at the last follow-up, the number of patients who reached the sUA target of 6 mg/dL and the number of gout attack between the groups. There were no significant differences in the change of eGFR and decrease of eGFR between the groups. There were 2 cases of AEs. One patient in CKD stage 3 had maculopapular rash and one patient in CKD stage 4/5 had dizziness. The AEs were subsided after febuxostat was stopped.

Conclusion

Febuxostat was efficacious and well tolerated in gout patients with CKD stage 4/5.

Copyright © 2019. Korean Association of Medical Journal Editors.